IL6 and systemic lupus erythematosus: TLR9 can play an important role in the pathogenesis of SLE [56,57], and it has been demonstrated that IVIg can suppress B cell TLR9 expression and decrease IL-6 and IL-10 production in ODN-CpG activated B cells [58].